As Horizon Pharma Plc (HZNP) Market Valuation Declined, Deerfield Management Company Lowered Its Holding by $8.05 Million; Air Products & Chemicals (APD) Shareholder Armstrong Henry H Associates Increased Its Holding by $1.04 Million as Market Value Declined

April 24, 2018 - By Ellis Scott

Air Products and Chemicals, Inc. (NYSE:APD) Logo

James E. Flynn decreased its stake in Horizon Pharma Plc (HZNP) by 8.32% based on its latest 2017Q4 regulatory filing with the SEC. Deerfield Management Company sold 575,176 shares as the company’s stock declined 6.58% with the market. The hedge fund run by James E. Flynn held 6.34 million shares of the major pharmaceuticals company at the end of 2017Q4, valued at $92.59 million, down from 6.92 million at the end of the previous reported quarter. Deerfield Management Company who had been investing in Horizon Pharma Plc for a number of months, seems to be less bullish one the $2.27B market cap company. The stock decreased 1.15% or $0.16 during the last trading session, reaching $13.78. About 831,529 shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has declined 6.20% since April 24, 2017 and is downtrending. It has underperformed by 17.75% the S&P500.

Armstrong Henry H Associates Inc increased its stake in Air Products & Chemicals (APD) by 24.68% based on its latest 2017Q4 regulatory filing with the SEC. Armstrong Henry H Associates Inc bought 6,350 shares as the company’s stock declined 2.93% with the market. The institutional investor held 32,080 shares of the basic industries company at the end of 2017Q4, valued at $5.26 million, up from 25,730 at the end of the previous reported quarter. Armstrong Henry H Associates Inc who had been investing in Air Products & Chemicals for a number of months, seems to be bullish on the $35.80 billion market cap company. The stock decreased 1.55% or $2.58 during the last trading session, reaching $163.53. About 573,801 shares traded. Air Products and Chemicals, Inc. (NYSE:APD) has risen 16.71% since April 24, 2017 and is uptrending. It has outperformed by 5.16% the S&P500.

Investors sentiment increased to 1.04 in Q4 2017. Its up 0.04, from 1 in 2017Q3. It is positive, as 30 investors sold HZNP shares while 53 reduced holdings. 33 funds opened positions while 53 raised stakes. 128.65 million shares or 2.76% less from 132.29 million shares in 2017Q3 were reported. Connor Clark & Lunn Inv Management Limited stated it has 265,204 shares or 0.02% of all its holdings. One Trading Lp holds 0.01% in Horizon Pharma Public Limited Company (NASDAQ:HZNP) or 68,340 shares. American Century Incorporated has invested 0% of its portfolio in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Qs Invsts Limited Liability Company accumulated 176,748 shares. Assetmark Inc holds 0% or 42 shares in its portfolio. Brandywine Global Ltd Company stated it has 4.16 million shares. Morgan Stanley reported 495,371 shares or 0% of all its holdings. Blackrock owns 13.45M shares for 0.01% of their portfolio. Franklin Res has invested 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Alps Advsr holds 0.02% of its portfolio in Horizon Pharma Public Limited Company (NASDAQ:HZNP) for 181,604 shares. Creative Planning accumulated 99,183 shares. New York-based Rothschild Asset Management has invested 0.27% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Glenmede Na invested 0.22% of its portfolio in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Sei Investments Com reported 280,591 shares. Fincl Architects stated it has 600 shares or 0% of all its holdings.

Among 13 analysts covering Horizon Pharma (NASDAQ:HZNP), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Horizon Pharma had 62 analyst reports since September 9, 2015 according to SRatingsIntel. The company was maintained on Friday, October 13 by Jefferies. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, September 15. The stock of Horizon Pharma Public Limited Company (NASDAQ:HZNP) earned “Buy” rating by Cantor Fitzgerald on Sunday, April 15. The firm has “Buy” rating given on Monday, August 7 by BMO Capital Markets. As per Tuesday, September 13, the company rating was maintained by Mizuho. The rating was downgraded by Brean Capital on Tuesday, September 22 to “Hold”. Morgan Stanley maintained the stock with “Equal-Weight” rating in Friday, March 2 report. UBS maintained the stock with “Buy” rating in Thursday, November 30 report. The company was upgraded on Friday, December 16 by Mizuho. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, November 6.

Deerfield Management Company, which manages about $4.41B and $2.54B US Long portfolio, upped its stake in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 54,984 shares to 262,984 shares, valued at $15.04M in 2017Q4, according to the filing. It also increased its holding in Immunomedics Inc (NASDAQ:IMMU) by 718,448 shares in the quarter, for a total of 1.30 million shares, and has risen its stake in Intersect Ent Inc (NASDAQ:XENT).

Analysts await Horizon Pharma Public Limited Company (NASDAQ:HZNP) to report earnings on May, 9 before the open. They expect $0.11 earnings per share, down 47.62% or $0.10 from last year’s $0.21 per share. HZNP’s profit will be $18.14 million for 31.32 P/E if the $0.11 EPS becomes a reality. After $0.29 actual earnings per share reported by Horizon Pharma Public Limited Company for the previous quarter, Wall Street now forecasts -62.07% negative EPS growth.

Air Products and Chemicals, Inc. (NYSE:APD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: